Get the Stockscreener App
1.89
5.50%
-0.11
After Hours:
1.8994
0.0094
+0.50%
CytomX Therapeutics Inc stock is currently priced at $1.89, with a 24-hour trading volume of 3.51M.
It has seen a -5.50% decreased in the last 24 hours and a +7.39% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.98 pivot point. If it approaches the $1.87 support level, significant changes may occur.
Previous Close:
$2.00
Open:
$1.95
24h Volume:
3.51M
Market Cap:
$147.27M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-2.25
EPS:
-0.84
Net Cash Flow:
$-56.88M
1W Performance:
-4.55%
1M Performance:
+7.39%
6M Performance:
+43.18%
1Y Performance:
+6.78%
1D Range:
$1.85
$1.97
52W Range:
$1.04
$5.85
CytomX Therapeutics Inc Stock (CTMX) Company Profile
Name
CytomX Therapeutics Inc
Sector
Industry
Phone
650-515-3185
Address
151 Oyster Point Boulevard, Suite 400, South San Francisco, CA
CytomX Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
CytomX Therapeutics Inc Stock (CTMX) Latest News
CytomX Therapeutics Announces New Employment Inducement Grants - Yahoo Finance
Yahoo Finance
CytomX Therapeutics Inc [CTMX] stock for 42175 USD was sold by McCarthy Sean A. – Knox Daily - Knox Daily
Knox Daily
CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Canada Shine On
Yahoo Canada Shine On
Top investors say CytomX Therapeutics Inc (CTMX) ticks everything they need – Sete News - SETE News
SETE News
Top Ranked Momentum Stocks to Buy for April 17th - Yahoo Movies UK
Yahoo Movies UK
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Are Not Doing Enough For Some Investors - Yahoo News Australia
Yahoo News Australia
CytomX Therapeutics Inc Stock (CTMX) Financials Data
CytomX Therapeutics Inc (CTMX) Revenue 2024
CTMX reported a revenue (TTM) of $101.21 million for the quarter ending December 31, 2023, a +90.38% rise year-over-year.
CytomX Therapeutics Inc (CTMX) Net Income 2024
CTMX net income (TTM) was -$569.00 thousand for the quarter ending December 31, 2023, a +99.43% increase year-over-year.
CytomX Therapeutics Inc (CTMX) Cash Flow 2024
CTMX recorded a free cash flow (TTM) of -$56.88 million for the quarter ending December 31, 2023, a +49.46% increase year-over-year.
CytomX Therapeutics Inc (CTMX) Earnings per Share 2024
CTMX earnings per share (TTM) was -$0.02 for the quarter ending December 31, 2023, a +98.68% growth year-over-year.
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
0.77%
1.20%
Cap:
|
Volume (24h):